Dr. Young most recently served as the chief medical officer of GTx, Inc., a public biopharmaceutical company focused on developing small molecules that target nuclear hormone receptors. Previously, she spent 13 years at Novartis Oncology in senior leadership roles in global clinical development and medical affairs. As the head of Oncology Clinical Development, she directed the clinical programs for EXJADE, GLIVEC, FEMARA, AFINITOR, RYDAPT, JAKAVI and FARIDAK among others. Prior to Novartis, she held senior leadership positions in clinical development at the R.W. Johnson Pharmaceutical Research Institute of Johnson & Johnson, Hoffman-La Roche and Sandoz.
"Dr. Young’s notable career and strong track record of successful drug development make her an important addition to Celldex," said Anthony Marucci, co-founder, president and chief executive officer of Celldex Therapeutics. "Her proven leadership will strengthen our clinical development efforts and support the continued progress of our product pipeline.”